News

Cancer Therapy Advisor1d
FDA Roundup: Oncology Drug Approvals in 2025
On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...
PharmExec3d
FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements
The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...
Independent Online29d
Pharmacist warns of hidden dangers of medication interactions
Contraindications are divided into two categories ... “Always consult a healthcare professional to ensure your OTC and prescription drugs are safe to use together,” Muhlarhi advises ...
Morningstar7d
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S ...
Eagle-Tribune8d
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ... expanding patient eligibility by reducing contraindications. CAMZYOS is the first and only ...